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Background: The recent decline in malaria incidence in many African countries has been attributed to the
provision of prompt and effective anti-malarial treatment using artemisinin-based combination therapy (ACT) and
to the widespread distribution of long-lasting, insecticide-treated bed nets (LLINs). At a malaria vaccine-testing site
in Bandiagara, Mali, ACT was introduced in 2004, and LLINs have been distributed free of charge since 2007 to
infants after they complete the Expanded Programme of Immunization (EPI) schedule and to pregnant women
receiving antenatal care. These strategies may have an impact on malaria incidence.
Methods: To document malaria incidence, a cohort of 400 children aged 0 to 14 years was followed for three to
four years up to July 2013. Monthly cross-sectional surveys were done to measure the prevalence of malaria
infection and anaemia. Clinical disease was measured both actively and passively through continuous availability of
primary medical care. Measured outcomes included asymptomatic Plasmodium infection, anaemia and clinical malaria
episodes.
Results: The incidence rate of clinical malaria varied significantly from June 2009 to July 2013 without a clear
downward trend. A sharp seasonality in malaria illness incidence was observed with higher clinical malaria incidence
rates during the rainy season. Parasite and anaemia point prevalence also showed seasonal variation with much higher
prevalence rates during rainy seasons compared to dry seasons.
Conclusions: Despite the scaling up of malaria prevention and treatment, including the widespread use of bed nets,
better diagnosis and wider availability of ACT, malaria incidence did not decrease in Bandiagara during the study
period.
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In the past few decades, new tools and strategies for
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therapy (ACT), long-lasting insecticide treated bed nets
(LLINs), intermittent preventive treatment in pregnancy
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children showed efficacy in malaria control [1,2]. Declines
in the malaria burden in many areas have been attributed
largely to the scaling up of these interventions [3].
In Mali, ACT was introduced in 2004 and LLINs have
been distributed free of charge since 2007 to infants
aged less than one year upon completion of their routine
Expanded Programme of Immunization (EPI) schedule.
These interventions have been routinely available in the
Malian town of Bandiagara since 2007. This town has
been the testing site for several malaria vaccine candidatesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of the malaria burden at other clinical trial sites
has been reported [8-10]. The clinical trials conducted
in Bandiagara have been planned on the basis of malaria
incidence data collected in 1999 to estimate sample sizes
[11]. Updated information on malaria infection and clin-
ical disease in the context of scaled-up malaria control in-
terventions is needed to plan new clinical trials of malaria
vaccines and other interventions and to estimate sample
sizes at this site.
The main objective of this study was to measure Plas-
modium falciparum malaria clinical disease in children
over the course of several consecutive malaria seasons
(from 2009 to 2013) in Bandiagara, Mali. The seasonal
prevalence of malaria infection and anaemia in children
and infants was also determined over this study period.Methods
Study area
The study was conducted in Bandiagara, a town of ap-
proximately 14,000 inhabitants located in central Mali,
on a rocky plain. The mean annual rainfall is about
600 mm. A small river, the Yame, runs through Bandia-
gara town. This river is a minor tributary of the Niger
that flows during the rainy season, and holds transient
post-rainfall standing water the rest of the year. Anoph-
eles gambiae s.l. complex are the main malaria vectors.
Malaria transmission is highly seasonal, with minimal
transmission during the dry season in March with essen-
tially no detectable infective mosquito bites. Transmission
occurs during the rainy season from July to November
with a peak of up to 60 infective mosquito bites per per-
son per month in August or September [12,13]. Plasmo-
dium falciparum represents 97% of malaria infections,
with the remaining 3% due mostly to Plasmodium malar-
iae and rare Plasmodium ovale infections.Subject recruitment and enrolment
After obtaining community permission as described by
Diallo et al. [14], the study was publicized by local radio
broadcast. Two rounds of participant recruitment were
done. Parents were invited to accompany children to the
Bandiagara Malaria Project (BMP) Research Clinic to be
screened for eligibility. Participants were enrolled on a
first-come, first-served basis until the target number in
each age strata was reached. In June 2009, a subcohort
of 300 children under six years of age was enrolled. An-
other subcohort of 100 children between seven and
14 years of age was enrolled in June 2010. One-hundred
children were included in each of four age categories:
under two years, three to four years, five to six years,
and seven to 14 years to permit age-specific malaria inci-
dence rate measurement.Inclusion and exclusion criteria
Children in the target age group were eligible for inclu-
sion in the study if they met all of the following criteria:
residency in Bandiagara town, general good health based
on clinical evaluation, aged under 14 years inclusive at the
time of screening, written informed consent obtained from
the parent/guardian, assent from children aged 13 years
and above, and availability to participate in follow-up for
the duration of study. Exclusion criteria were: simultan-
eous participation in an interventional clinical trial and
chronic use of a medication with known anti-malarial ac-
tivity, such as trimethoprim-sulphamethoxazole.
Ethical clearance
The study protocol and informed consent/assent process
were reviewed and approved by the institutional review
boards of the Faculty of Medicine, Pharmacy and Dentistry
of the University of Sciences, Techniques and Technolo-
gies of Bamako and the University of Maryland School of
Medicine. Permission to work in the community was ob-
tained from local official authorities. Individual written in-
formed consent was obtained from parents or guardians
and assent was obtained from children aged 13 years and
older.
Study procedures
Active surveillance consisted of scheduled monthly visits
(every four weeks) with the aim of detecting asymptom-
atic malaria infection and anaemia. At each visit, partici-
pants were questioned for symptoms of malaria and
examined. Finger-prick blood was collected for malaria
thick smear and haemoglobin level. Smears were not
read contemporaneously unless symptoms or signs of
malaria were present. At enrolment, glucose-6-phoshate
dehydrogenase (G6PD) deficiency and haemoglobin type
were determined. Passive surveillance consisted of con-
tinuous availability of free, basic medical care at the
BMP Research Clinic and Bandiagara District Hospital.
Parents/guardians were encouraged to visit the clinic
at any time if their child became sick. Children were
examined by a physician. If symptoms or signs com-
patible with malaria were present, finger-prick blood
was collected for a blood film, which was read imme-
diately. Uncomplicated malaria was treated with ACT
(artesunate/amodiaquine or artemether/lumefantrine) ac-
cording to the guidelines of the Mali National Malaria
Control Programme. Parents/guardians were instructed
to administer only drugs given or prescribed by the
research team. Two definitions for clinical malaria were
used: (i) a broader definition based on treatment-seeking
behaviour, clinical symptoms consistent with malaria and
presence of malaria parasites at any density; and, (ii) a
more specific definition with parasite density ≥2,500 para-
sites per microlitre, body temperature ≥37.5°C, and










Male 49 40 53 22 27 191
Female 39 58 61 14 37 209
Total 88 98 114 36 64 400
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aches, joint pain, vomiting, diarrhoea, or abdominal pain.
Anaemia was defined as a haemoglobin level <10 g/dL.
Sample size estimation
To adequately estimate malaria incidence, an average of
0.75 clinical malaria episodes per subject per year, a confi-
dence level of 95%, and a Poisson distribution of malaria
were assumed. With the above assumption, 400 total sub-
jects, 100 subjects in each age category (under two years,
three to four years, five to six years, and seven to 14 years)
were needed to estimate the age category-specific malaria
incidence with a confidence interval of +/− 0.20 clinical
episodes per subject per year.
Laboratory assays
Malaria thick smears were Giemsa-stained and parasites
counted against 300 leukocytes to give parasite counts/
mm3, assuming a leukocyte count of 7,500/mm3. Stand-
ard operating procedures were developed to ensure uni-
form and high-quality malaria smears, including training
and qualifying malaria microscopists. Haemoglobin type
was determined by high-performance liquid chromatog-
raphy (D-10 instrument; Bio-Rad). Restriction fragment
length polymorphism analysis was used to identify the
(A-) allele of the G6PD deficiency, as previously de-
scribed (15). Haemoglobin determinations were made
using Hemocue haemoglobin analyzers (Hemocue Inc,
Cypress, CA, USA).
Statistical methods
Data were double-entered and then reconciled using
Microsoft ACCESS 2007. The analysis was performed
using STATA software, version 12 (Stata Corp, College
Station, TX, USA). Descriptive statistics were used to
summarize baseline values and demographic characteris-
tics (age, gender, ethnicity, and neighbourhood). Pearson
Chi-square tests or exact probabilities statistics were
used to compare categorical variables. Multivariate ana-
lysis using Poisson regression was performed to estimate
the risk ratio of malaria episode adjusting for covariates.
All p values <0.05 were considered statistically significant.
Age-specific incidence rates (the number of episodes per
person over the study period) of clinical malaria were cal-
culated. Clinical malaria episodes separated by at least
14 days were considered distinct, separate illnesses. The
follow-up time was four consecutive years for participants
under six years old and three consecutive years for partici-
pants aged seven to 14 years.
Results
Sociodemographic and baseline characteristics
A total of 519 participants were screened (405 under six
years old and 114 aged seven to 14 years). Of these, 400that met inclusion criteria were enrolled, (300 aged under
six years and 100 aged seven to 14 years). Main reasons
for exclusion were willingness to travel out of the study
area and parents’ refusal. The sex ratio was 0.9 (191 boys
vs 209 girls, (Table 1)). The mean age was 3.6 years (95%
CI (3.4-3.8)) for children aged under six years and 11 years
(95% CI (10.58-11.42)) for older children. Dogon was the
main ethnic group (74%). Haemoglobin AA was the most
frequent phenotype (78.8%). Other phenotypes include
haemoglobin AC (13%), haemoglobin AS (6.3%), haemo-
globin CC (1.2%), and haemoglobin SC (0.7%) (Table 2).
Thirty-eight participants (9.5%) had G6PD deficiency
(Table 3). Among G6PD-deficiency carriers, 17% were
hemizygous, 16% heterozygous and 5% homozygous.
Clinical malaria
With malaria defined using a minimum parasite density
threshold, 1,193 episodes of clinical malaria were en-
countered. When a broader malaria case definition was
used irrespective of body temperature at the time of
clinic visit, a total of 1,908 clinical episodes were docu-
mented (1,494 and 414 clinical malaria episodes in the
younger and older subcohorts, respectively). Among
children aged under six years, 85.7% of those who expe-
rienced clinical malaria had fever. In patients diagnosed
with clinical malaria, symptoms included history of fever
(90.7%), headache (65.5%), vomiting (34.3%), abdominal
pain (17.7%), and diarrhoea (6.7%). Approximately 97%
(1,842/1,908) of children reported sleeping under a bed
net since their previous scheduled visit. Most of these
bed nets (90.9%) were insecticide-treated.
Overall, six severe malaria cases occurred during the
study, all in children aged three to 11 years. Their symp-
toms were coma in two cases, seizures in three cases
and lethargy in one case. All had normal haemoglobin
(AA) and normal G6PD status.
The overall annual incidence rate was 1.4 clinical mal-
aria episodes (clinical symptoms consistent with malaria
and presence of parasite at any density) during study
period. The incidence was much higher from June to
December compared to the levels observed from January
to May (Table 4). The annual incidence rates were 1.7, 2.0,
1.9, and 3.3, respectively, in transmission seasons 2009,
2010, 2011, and 2012 (Figure 1). There was an association
between malaria incidence and age in 2009. The youngest
children (aged less than two years old) had fewer episodes
Table 2 Haemoglobin type distribution per ethnic group
Ethnics AA AC AS CC SC Total
Bambara 15 3 1 0 1 20
Dogon 230 44 15 5 1 295
Peulh 31 1 4 0 0 36
Sonrhaï 15 2 3 0 1 21
Others 24 2 2 0 0 28
Total 315 (78.8%) 52 (13%) 25 (6.3%) 5 (1.2%) 3 (0.7%) 400
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years (RR = 0.63, 95% CI (0.46-0.85); p = 0.002). No similar
association between malaria incidence and age was ob-
served in years that followed. Also, haemoglobin type C
was associated with protection against malaria (RR = 0.59,
95% CI (0.40-0.89); p = 0.012). G6PD deficiency was not
associated with protection against clinical malaria (RR =
0.88, 95% CI (0.60-1.30); p = 0.539) (Table 5).
Prevalence of infection
The highest average point prevalence of parasitaemia
were observed from August to November of each study
year for all age categories. The lowest prevalence of in-
fection observed was 3, 1.1, 1.4, 0.3 and 0.6%, respect-
ively, in 2009, 2010, 2011, 2012, and 2013. The highest
prevalence of infection was 10.7, 12.9, 24.1, 28.7, and
13.3%, respectively, in 2009, 2010, 2011, 2012, and 2013
(Figure 2).
Prevalence of anaemia
Monthly time point prevalence of anaemia was 19.7,
13.8, 6.2, 6.9, and 24.9%, respectively, in 2009, 2010,
2011, 2012, and 2013 (Figure 3). The highest prevalence
of anaemia was observed from September to October for
all study years. For instance, in October 2009 the younger
children (<five years old) were more affected compared to
the older age group (≥five years old); the anaemia preva-
lence was 22.6% (66/292) and 5.1% (15/292), respectively,
p < 0.001.
Discussion
Decreases in malaria incidence have been observed in
parts of Africa following prompt and effective anti-
malarial treatment with ACT in conjunction with theTable 3 G6PD deficiency distribution per ethnic group
Ethnics Normal Deficiency Total (%)
Bambara 20 0 20
Dogon 266 29 295
Peulh 32 4 36
Sonrhaï 19 2 21
Others 25 3 28
Total 362 (90.5%) 38 (9.5%) 400widespread use of LLINs [1,2]. Bandiagara, Mali has
been developed as a site for testing malaria vaccines. In
the context of nationwide scale up of malaria control ef-
forts, it was necessary to update age-specific incidence
of malaria infection for sample size determination of fu-
ture efficacy trials of malaria vaccine candidates and
other interventions at this site.
A closed cohort of 400 children was followed using ac-
tive and passive surveillance over four years. Continuous
availability of free, expeditious, high-quality medical
care, including rapid microscopic diagnosis of malaria,
along with study investigators long experience in the site
and good rapport with the population, provided confi-
dence that the follow-up procedures captured all clinical
malaria episodes that occurred in the cohort during the
study period. For the purpose of analyses, two age strata
were defined, with an age threshold set at five years. This
allowed to consider the group of children aged less than
five years, which represent the most vulnerable group to
malaria. Children under five years old are also the target
population for World Health Organization policy recom-
mendation on the use of SMC [15].
Annual clinical malaria incidence was remarkably stable
in this well-characterized and closely followed cohort over
four years. Moreover, a statistically significant increase in
clinical malaria incidence was reported in the 2012 trans-
mission season, probably due to more abundant rainfall
that year. These results contrast with data recently pub-
lished that showed a significant decrease in malaria bur-
den in Senegal [10], Kenya [16], Rwanda [17], and Zambia
[18]. A systematic review covering data from 39 studies
conducted in 16 African countries from 1987 to 2007
compared the proportion of fever associated with P. fal-
ciparum before 2000 and afterwards. The proportion of
fever associated with P. falciparum decreased by 50% in
the period after 2000 [19]. However, a closer look at the
data from Kenya showed a more complex pattern, with
districts where malaria burden was reduced and others
where malaria-associated hospital admissions sharply in-
creased. In addition, changes in malaria burden appear to
have occurred before scaling up of malaria control inter-
ventions [20]. There have been increases in malaria-
associated hospital admissions in Uganda [21]. Thus
decreases in the malaria burden following scaling up of
malaria interventions in Africa have not occurred uni-
formly. The factors affecting measures of malaria burden
may be complex - for example, initial increases in hospital
admissions reported in some countries could in part re-
flect changing treatment-seeking behaviour patterns due
to health education and outreach that ultimately lead to
substantial decreases in disease burden as it has been de-
scribed in Senegal [10].
Data from this cohort differ from large population-
based studies and several hospital record-based analyses
Table 4 Malaria Incidence rate by year and per transmission season
Years Transmission season** Number of cases Person-year Incidence rate *IRR (95% CI) p
2009*** High transmission season 276 157 1.7 Ref
2010 Overall 456 324 1.4
Low transmission season 32 115 0.3
High transmission season 424 208 2 1.15 (0.99–1.35) 0.05
2011 Overall 458 352 1.3
Low transmission season 58 149 0.4
High transmission season 400 202 1.9 1.12 (0.96–1.31) 0.11
2012 Overall 672 335 2
Low transmission season 25 141 0.2
High transmission season 647 196 3.3 1.87 (1.62–2.16) <0.001
2013 Low transmission season 46 192 0.2
*IRR = Incidence rate ratio for high transmission season; 95% CI is 95% confidence interval.
**Transmission season; High transmission season was from June-December (rainy season) and low transmission season was from January-May (dry season).
***2009 high transmission season was used as reference (Ref) in estimating IRR for other years during high transmission season.
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high coverage of control interventions, this should have
produced an impact that would also be observed in this
cohort. Achieving universal coverage in control interven-
tions has been advocated by Roll Back Malaria since 2005
[22,23]. The level of coverage in malaria control interven-
tions in Bandiagara, a town of 14,000 inhabitants has not
been systematically determined for this study. The Malian
National Malaria Control Programme started implement-
ing its new strategy in 2007. This new strategy included
free nationwide distribution of LLINs to all children aged
less than five years and to all pregnant women, malaria
treatment based on ACT and rapid diagnostic tests free of
charge for all children aged less than five years. In its 2012
report, the Mali National Malaria Control Programme
documented 96% coverage of the target population in
Bandiagara with the primary control interventions (LLINsFigure 1 Malaria Incidence rate by year and per transmission season.and IPTp) [24]. Stable incidence of malaria reported here
was determined in a cohort that benefited from the same
interventions that were carried out in the larger commu-
nity in Bandiagara. In addition, the researcher verified that
all children from the cohort benefited from the National
Malaria Control Programme interventions to avoid any
ethical injustice because of their inclusion in the study.
It is noteworthy that during the 2000–2010 decade, the
town of Bandiagara benefited from major urbanization
with new infrastructure, such as new dwellings, asphalt-
paved roads, rainwater drain canals, electricity, and water
supply. These changes have profoundly affected the local
micro-epidemiology of malaria. Clinical malaria cases
are distributed in time-space clusters in Bandiagara
[25]. The characteristics of these clusters are determined
by the local conditions created by the environment change
at a local scale; these clusters may be prone to malaria
Table 5 Incidence rate ratio estimates in year 2009
adjusting for covariates
Covariates IRR* (95% CI) p
3-4 years 0.93 (0.70-1.23) 0.623
<2 years 0.63 (0.46-0.85) 0.002
G6PD deficiency 0.88 (0.60-1.30) 0.539
Haemoglobin C 0.59 (0.40-0.89) 0.012
Haemoglobin AS 0.78 (0.42-1.45) 0.442
*IRR: Incidence rate ratio estimated using Poisson regression; ≥5 years old,
normal G6PD deficiency and normal haemoglobin type were used as
reference. CI is the 95% confidence interval.
Figure 2 Monthly prevalence of asexual Plasmodium sp. carriage per
B (children above 5 years old).
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ing on the effects of these infrastructure changes.
Bandiagara has a Sahelian setting with annual rainfall
concentrated over three months and a long dry season
where previous studies have detected no infected mos-
quitoes. Malaria transmission is sharply seasonal. In this
cohort, follow-up was continued during the dry season,
and a persistence of clinical malaria that was not re-
ported before, was observed. The incidence rate was
much lower, with approximately one clinical episode of
malaria occurring once in every five children, but at this
low level, malaria transmission persisted throughout the
dry season.
Classically, malaria incidence is higher in younger chil-
dren in high transmission settings [26]. In this study, less
clinical malaria was seen in younger children as comparedyear and per age categories A (children under 5 years old)
Figure 3 Monthly prevalence of anaemia per year and per age categories A (children under 5 years old) B (children above
5 years old).
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follow-up only. This observation is supported by other
data, that as malaria transmission decreases, there is a
shift in the age group that bears the highest disease bur-
den [27]. Other entomological parameters of transmission
were not concomitantly measured. Parasite prevalence
rates regularly assessed are lower than levels determined
several years ago at the same site [11]. WHO recommends
that SMC be applied to children aged under five years old
in areas such as Bandiagara, where 60% of malaria trans-
mission is concentrated in three to four months each year.
The results reported here call for an extension of the SMC
age group to include children older than five years old.
Others have reached similar conclusions using modelling
approaches on large-scale data sets [26]. The upper level of
the age group was not determined in this study. Children
up to 15 years old were enrolled. However, it is likely thatthe adult population in Sahelian regions bear a heavy mal-
aria burden [28]. More data on malaria distribution in this
older age group are urgently needed in African Sahelian
countries in view of increased efforts at malaria elimination.
Conclusion
These results indicate an absence of decline in malaria in-
cidence following the scaling up of malaria prevention and
control measures since 2004, including the widespread
use of LLINs, better diagnostics and a wider availability of
ACT. Malaria transmission was seasonal in Bandiagara;
93% of cases occurred from June to December. In view of
the prospect of large-scale implementation of SMC, a new
WHO-recommended control strategy for Sahelian coun-
tries is important to re-examine the target age group and
consider extending it to include children older than five
years old.
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